Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POTIGA is an oral small-molecule tablet approved by GSK in June 2011. The specific indication and mechanism of action are not publicly detailed in available data, but it represents a non-biologic therapeutic agent. The drug is currently in peak commercial lifecycle, indicating established market presence.
Peak
Peak lifecycle suggests stable-to-maturing revenue; commercial team likely focused on market maintenance and competitive differentiation rather than launch activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POTIGA roles are currently at zero linked job openings, indicating a mature, stable franchise. Positions on this product would emphasize market retention, payer management, and competitive strategy rather than launch execution or pipeline development.
Brand ManagerMedical Science Liaison
Worked on POTIGA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.